1. Home
  2. CHRD vs SYRE Comparison

CHRD vs SYRE Comparison

Compare CHRD & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chord Energy Corporation

CHRD

Chord Energy Corporation

SELL

Current Price

$145.79

Market Cap

8.4B

Sector

Energy

ML Signal

SELL

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

SELL

Current Price

$94.12

Market Cap

8.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CHRD
SYRE
Founded
2007
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
8.7B
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
CHRD
SYRE
Price
$145.79
$94.12
Analyst Decision
Buy
Strong Buy
Analyst Count
18
18
Target Price
★ $182.75
$123.87
AVG Volume (30 Days)
769.9K
★ 876.8K
Earning Date
11-04-2026
11-03-2026
Dividend Yield
★ 3.54%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 14.47
N/A
Revenue
N/A
N/A
Revenue This Year
$53.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.15
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.35
$23.01
52 Week High
$159.96
$110.64

Technical Indicators

Market Signals
Indicator
CHRD
SYRE
Relative Strength Index (RSI) 50.91 47.08
Support Level $130.54 $93.28
Resistance Level $152.12 $104.15
Average True Range (ATR) 5.62 5.16
MACD 0.19 -0.52
Stochastic Oscillator 56.81 10.58

Price Performance

Historical Comparison
CHRD
SYRE

About CHRD Chord Energy Corporation

Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: